Topical Corticosteroids Market, by Formulation (Creams, Ointments, Gels, Others), by Application (Acne, Dermatitis, Psoriasis, Eczema, Hyperpigmentation, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Topical steroids are available in a variety of strengths and are classified into seven classes based on their potency. Class I (class one) contains the strongest steroids, while Class VII contains the weakest (class seven).
Topical steroids in Class I are 600 to 1,000 times more powerful than those in Class VII. The right steroid strength, or potency, is determined by a number of factors.
Babies, for example, absorb topical steroids much faster than adults, so a low-potency steroid may be required.
Topical steroids are absorbed quickly in parts of the body where skin touches flesh, such as the armpits or beneath the breasts, or in sensitive areas of skin, such as the eyelids, and may only require a low-potency formulation.
Market Dynamics
Market players are focused on launching generic products, this is expected to contribute to growth of the global topical corticosteroids (steroids) market over the forecast period. For instance, in March 2019, Lupin Limited, an Indian pharmaceutical company announced the launch of Fluocinonide Ointment USP, 0.05 %, which was approved by the US Food and Drug Administration (FDA) in July 2018. Lupin's Fluocinonide Ointment USP, 0.05% is the generic equivalent of County Line Pharmaceuticals LLC's Lidex Ointment 0.05%. It is used to treat inflammatory and pruritic symptoms associated with corticosteroid-responsive dermatoses.
Market players are involved in strategies such as acquisitions, which is expected to contribute to growth of global topical corticosteroids (steroids) market. For instance, in October 2018, Mayne Pharma, a specialty pharmaceutical company, announced that it has acquired the US and Australia rights to halobetasol foam 0.05% for US$32.0 million. Halobetasol foam is a highly potent corticosteroid that is used to treat plaque psoriasis.
Increasing initiatives by non-profit organizations for better treatment of eczema is expected to aid growth of the global topical corticosteroids (steroids) market over the forecast period. For instance, in September 2021, on world eczema day (September 14), eleven patient organizations from eight countries came together to launch the Global Patient Initiative to Improve Eczema Care (GPIIEC). The programme is a global effort to develop a uniform "yardstick" for evaluating how well health systems respond to demands of patients and their caregivers. This groundbreaking collaboration has discovered aspects of health-care delivery that matter most to patients and caregivers, as well as indicators to assess them across eight developed countries (Australia, Canada, Denmark, France, Italy, Germany, United States, and the United Kingdom).
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook